Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026

Interest in peptides is growing among both patients and prescribers, and despite favorable Pharmacy Compounding Advisory Committee (PCAC) votes, pharmacists must stay vigilant and help patients understand the quality concerns tied to these emerging products.

In a discussion surrounding his NCPA 2026 session titled “How to Navigate the Evolving Peptide Landscape,” Matt Martin, PharmD, BCSCP, vice president of clinical services at PCCA, provided expert insights regarding the clinical and regulatory peptide landscapes. As patients bring questions from social media and other areas to the pharmacy counter, pharmacists are increasingly responsible for explaining that these products can’t yet be compounded and that “research use only” vials sold online may carry serious quality risks.

“Patients are really looking for other opportunities to address their health challenges as well as improve the quality of their health span,” Martin told Drug Topics®. “As they're looking for information, certainly from traditional sources [like] physicians, practitioners, [and] pharmacists, they're also seeking a lot of information through social media platforms, podcasts, other online sources, and finding information about these peptides, and then bringing those questions back to the pharmacy counter.”

READ MORE: Q&A: Emerging Compounded Therapies Demand Pharmacist’s Clinical Judgment | NCPA 2026

Understanding the Regulatory Reality Behind PCAC Votes

Although PCAC voted to recommend 6 unapproved peptides for inclusion on the Section 503A bulks list during its recent meeting, Martin emphasized that advisory votes do not grant legal authorization to compound. Under federal standards, state-licensed 503A compounding pharmacies can legally prepare customized medications only if a drug possesses an official USP monograph, forms a component of an FDA-approved product, or appears on the final bulks list.^1,2

The panel recommended substances like BPC-157 and TB-500 despite FDA scientific staff objections regarding incomplete chemical characterization and a lack of human clinical trials. Until the agency completes formal notice and comment rulemaking or places these compounds onto an interim Category 1 guidance list, compounding these peptides remains technically unlawful.

This regulatory gap underscores why educational sessions at events like NCPA 2026 are crucial for helping practitioners understand the legal boundaries governing their practice.

Differentiating Approved Therapies from Gray Market Products

Peptides are short chains of amino acids that act as cellular signaling messengers throughout the human body. More than 80 peptide formulations, including long-standing treatments like insulin and modern GLP-1 receptor agonists such as semaglutide and tirzepatide, are fully FDA approved for clinical use.^2,3

However, patients frequently confuse these well-studied therapies with unapproved compounds promoted across social media for anti-aging, weight loss, or muscle recovery. Seeking alternative avenues for wellness, consumers often turn to online suppliers or telehealth platforms. Many of these unapproved products originate from overseas distributors who evade federal oversight by adding labels stating the items are intended solely for research purposes.^3,4

Pharmacists play an essential role in clearing up patient confusion by verifying drug sources, evaluating clinical evidence, and clarifying whether a product is FDA approved.⁴

Quality Risks and the Crucial Role of Pharmacist Counseling

Beyond legal uncertainty, unapproved peptides present substantial quality and safety hazards that pharmacists must clearly communicate at the counter. Martin pointed out that unvetted products sold online are not evaluated for microbial contamination, endotoxins, or heavy metal impurities.³

Medical experts and FDA scientists caution that unapproved peptides carry potential risks of severe allergic reactions, immunogenicity, or unstudied tumor-promoting effects. Just because a product is packaged in a vial that resembles a legitimate injectable drug does not mean it meets safe manufacturing standards.^1-3

Pharmacists must actively counsel patients on these hidden dangers, slowing down discussions to ask targeted questions about where a product was obtained and who prescribed it.⁴

Practical Guidance for Pharmacy Professionals Moving Forward

To navigate this evolving environment ethically, Martin advises pharmacists to remain educated on peptide pharmacology and stay updated on federal rulemaking. Practitioners should align their guidance with established medical literature while actively participating in professional associations such as NCPA, APhA, or APC to receive timely policy updates.

Although proponents argue that bringing peptides into regulated 503A pharmacies would establish necessary safety guardrails against an unchecked gray market, practitioners must strictly follow the current law until formal changes occur. By maintaining supply chain integrity and fostering open dialogue with patients and prescribers, pharmacists can serve as trusted clinical guides while protecting public health in the peptide environment.^1,2,4

READ MORE: NCPA Annual Convention & Expo Resource Center

REFERENCES

1. Mercer A. Compounded peptides on the loose: what the recent PCAC meeting means for industry. Sheppard. August 7, 2026. Accessed October 12, 2026. https://www.sheppard.com/insights/blogs/compounded-peptides-on-the-loose-what-the-recent-pcac-meeting-means-for-industry

2. Nowosielski B, Lee D, Morgan L. Pharmacy Law Lowdown: FDA’s evaluation of peptides. Drug Topics. September 25, 2026. Accessed October 12, 2026. https://www.drugtopics.com/view/pharmacy-law-lowdown-fda-s-evaluation-of-peptides

3. Berg M. Peptide therapy: benefits, risks, and what you need to know. Safe Medication. April 27, 2026. Accessed October 12, 2026. https://www.safemedication.com/pharmacist-insights/2026/04/27/peptide-therapy-benefits-risks-and-what-you-need-to-know

4. Peptides are showing up at the pharmacy counter. Here’s what pharmacists should know. NimbleRx. Accessed October 12, 2026. https://www.nimblerx.com/articles/peptides-are-showing-up-at-the-pharmacy-counter-heres-what-pharmacists-should-know